Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PROCEPT BioRobotics (PRCT) Shares Outstanding (Diluted Average) (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $55.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 6.56% to $55.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $55.5 million, a 6.56% increase, with the full-year FY2025 number at $55.5 million, up 6.56% from a year prior.
  • Shares Outstanding (Diluted Average) was $55.5 million for Q4 2025 at PROCEPT BioRobotics, roughly flat from $55.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $55.7 million in Q3 2025 to a low of $4.8 million in Q1 2021.
  • A 5-year average of $41.1 million and a median of $45.6 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): soared 807.97% in 2022, then grew 1.58% in 2023.
  • PROCEPT BioRobotics' Shares Outstanding (Diluted Average) stood at $16.5 million in 2021, then surged by 169.42% to $44.4 million in 2022, then rose by 6.43% to $47.3 million in 2023, then increased by 10.31% to $52.1 million in 2024, then increased by 6.56% to $55.5 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Shares Outstanding (Diluted Average) are $55.5 million (Q4 2025), $55.7 million (Q3 2025), and $55.2 million (Q2 2025).